|
Close monitoring of the blood pressure is required during therapy. CARDENE I.V. is contraindicated in patients with known
hypersensitivity to the drug and in patients with advanced aortic stenosis. Reduction of diastolic pressure and
reduced afterload may worsen rather than improve myocardial oxygen balance. Caution is advised when administering CARDENE I.V.
to patients with impaired renal or hepatic function, in combination with beta-blocker in patients with CHF, or portal hypertension.
Observe caution in patients with significant left ventricular dysfunction due to possible negative inotropic effect. CARDENE I.V.
gives no protection against the dangers of abrupt beta-blocker withdrawal; beta-blocker dosage should be gradually reduced.
Levels of cyclosporine should be closely monitored during therapy. The most common side effects of CARDENE I.V. are headache (14.6%),
hypotension (5.6%), nausea/vomiting (4.9%), and tachycardia (3.5%). Less frequent adverse effects, in each case occuring at 1.4%,
including ECG abnormalities, postural hypotension, ventricular extrasystoles, injection-site reaction, dizziness, sweating and polyuria.
|
